NCT03389347View on ClinicalTrials.gov

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

NAActive, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 14, 2018

Primary Completion Date

December 19, 2024

Study Completion Date

December 19, 2026

Conditions
Plasma Cell LeukemiaRecurrent Multiple MyelomaRefractory Multiple Myeloma
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of bone marrow aspirate and blood

DEVICE

High Throughput Screening

Anti-tumor drugs are tested against myeloma cells in the laboratory, in a high-throughput drug sensitivity assay

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
lead

University of Washington

OTHER

NCT03389347 - High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | Biotech Hunter | Biotech Hunter